What is claimed is:

1. A method for treating a subject afflicted with multiple sclerosis comprising administering to the subject a therapeutically effective amount of soluble receptor for advanced glycation endproducts (sRAGE).

2. The method of claim 1, wherein the subject is human.

3. The method of claim 1, wherein the therapeutically effective amount of sRAGE is an amount between about 150 µg sRAGE/kg of subject/day and 15 mg sRAGE/kg of subject/day, or its equivalent.

4. The method of claim 1, wherein the therapeutically effective amount of sRAGE is an amount between about 500 µg sRAGE/kg of subject/day and 5 mg sRAGE/kg of subject/day, or its equivalent.

5. The method of claim 1, wherein the therapeutically effective amount of sRAGE is about 1.5 mg/kg of subject/day, or its equivalent.

6. A method for inhibiting $CD4^+$ T-cell migration comprising contacting the $CD4^+$ T-cell with soluble receptor for advanced glycation endproducts (sRAGE).

7. The method of claim 6, wherein the $CD4^+$ T-cell is a human cell.

8. The method of claim 6, wherein the $CD4^+$ T-cell is present in a subject, and the contacting with sRAGE is performed by administering a therapeutic amount of sRAGE to the subject.

9. The method of claim 8, wherein the subject is human.

10. The method of claim 8, wherein the therapeutically effective amount of sRAGE is an amount between about 150 µg sRAGE/kg of subject/day and 15 mg sRAGE/kg of subject/day, or its equivalent.

11. The method of claim 8, wherein the therapeutically effective amount of sRAGE is an amount between about 500 µg sRAGE/kg of subject/day and 5 mg sRAGE/kg of subject/day, or its equivalent.

12. The method of claim 8, wherein the therapeutically effective amount of sRAGE is about 1.5 mg/kg of subject/day, or its equivalent.

13. A method for inhibiting chemokine receptor activation in a subject comprising administering to the subject a therapeutically effective amount

of soluble receptor for advanced glycation endproducts (sRAGE).

14. The method of claim 13, wherein the subject is human.

15. The method of claim 13, wherein the chemokine receptor is selected from the group consisting of CCR1, CCR2, CCR5, CXCR2, CXCR4, VCAM-1, VLA-4, MMPS receptor, RANTES receptor, MIP-1β receptor, MIP-1a receptor, MIP-2 receptor, JE/MCP-1 receptor and TCA-3 receptor.

16. The method of claim 13, wherein the therapeutically effective amount of sRAGE is an amount between about 150 µg sRAGE/kg of subject/day and 15 mg sRAGE/kg of subject/day, or its equivalent.

17. The method of claim 13, wherein the therapeutically effective amount of sRAGE is an amount between about 500 µg sRAGE/kg of subject/day and mg sRAGE/kg of subject/day, or its equivalent.

18. The method of claim 13, wherein the therapeutically effective amount of sRAGE is about 1.5 mg/kg of subject/day, or its equivalent.

19. An article of manufacture comprising (a) a packaging material having therein soluble

receptor for advanced glycation endproducts (sRAGE) and (b) instructions for using the sRAGE in treating multiple sclerosis.

20. An article of manufacture comprising (a) a packaging material having therein soluble receptor for advanced glycation endproducts (sRAGE) and (b) instructions for using the sRAGE in inhibiting $CD4^+$ T-cell migration in a subject.

21. An article of manufacture comprising (a) a packaging material having therein soluble receptor for advanced glycation endproducts (sRAGE) and (b) instructions for using the sRAGE to inhibit cytokine receptor activation in a subject.